1 (135 15)
Lapatinib Tablet, Film Coated
Product Images NDC 42291-035
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Lapatinib (NDC 42291-035). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by Avkare, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Product Images & Figures Index
Chemical Structure (Image 1)
Figure 1 (Image 2)
This document provides information about a treatment plan involving Capecitabine and Lapatinib for the progression-free survival of patients. Dosage details for Capecitabine (2,500 mg/m²) and Lapatinib (1,250 mg) combined with Capecitabine (2,000 mg/m²) are included. The chart appears to show a cumulative progression-free time frame in weeks.*
Figure 2 (Image 3)
This data appears to be related to a cumulative progression-free analysis involving the administration of Capecitabine and Lapatinib at specified dosages over a period of time in weeks. The chart seems to track the efficacy of the treatment regimen in preventing disease progression.*
Figure 3 (Image 4)
This text outlines a chart showing the cumulative progression-free data over time for different treatments including Letrozole (2.5 mg) and a combination of Lapatinib (1,500 mg) with Letrozole (2.5 mg). The x-axis indicates time in weeks, ranging from 80 to 220 weeks.*
Figure 4 (Image 5)
This text provides a table showing different treatment combinations involving Trastuzumab, Lapatinib at two different doses, and Al at various timepoints. The table displays the timeframe in months since randomization.*
* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.
